A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances surv...
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights • DNA vaccine technology fusing cancer antigens to CD40L soluble multi-trimers. • Allows targeting of vaccine antigens to dendritic cells in situ. • Activates and matures dendritic cells. • Vaccine induces an anti-tumor immune response when combined with IL-12 and GM-CSF.
Alternative Titles
Full title
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4562804
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4562804
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2015.07.081
